A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/445 (2006.01) A61K 9/70 (2006.01) A61K 31/439 (2006.01)
Patent
CA 2212874
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-[4-(butylthio)-1,2,5-thiadiazol- 3-yl]-1-azabicyclo-[2.2.2]octane transdermal formulation. The invention provides desired transdermal 3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1- azabicyclo[2.2.2]octane patch formulations.
La présente invention décrit un procédé pour traiter un état pathologique associé à la modulation du récepteur muscarinique à l'aide d'une formulation transdermique 3- [4-(butylthio)-1, 2, 5-thiadiazol-3-yl]-1-azabicyclo-[2.2.2]octane. L'invention décrit des formulations transdermiques souhaitées 3- [4-(butylthio)-1, 2, 5-thiadiazol-3-yl]-1-azabicyclo-[2.2.2]octane sous forme de timbres.
Bymaster Franklin Porter
Shannon Harlan Edgar
Shipley Lisa Ann
Valia Kirti Himatlal
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Transdermal formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal formulation will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2050872